NGS Market Size, Share, Growth, and Industry Analysis, By Type (NovaSeq,NextSeq,Sequel,NanoporeS), By Application (Academic Institutes & Research Centers,Hospitals & Clinics,Pharmaceutical & Biotechnology Companies,Others), Regional Insights and Forecast to 2035

NGS Market Overview

The global NGS Market is forecast to expand from USD 9358.42 million in 2026 to USD 10573.14 million in 2027, and is expected to reach USD 28068.3 million by 2035, growing at a CAGR of 12.98% over the forecast period.

The market analysis indicates that 62% of hospitals in developed regions have integrated NGS testing for oncology, while 48% of academic research centers apply NGS in personalized medicine. Industry reports show that sequencing throughput has increased 40-fold over the last decade, making large-scale studies more accessible and cost-effective. Future scope lies in clinical diagnostics, as 35% of cancer patients in 2024 underwent NGS-guided treatment planning. With more than 110 countries funding genomic medicine initiatives, the market forecast projects strong opportunities across oncology, rare disease diagnosis, and population genomics. Market insights emphasize that technological advances such as single-cell sequencing and liquid biopsy integration will further expand the NGS market size, market share, and industry growth by 2033.

In the USA, the NGS market is expanding rapidly, with more than 520,000 genome sequences completed in 2024 across academic, hospital, and private labs. Market research reports highlight that 72% of U.S. cancer centers utilize NGS testing for precision oncology, while 61% of rare disease diagnostics incorporate NGS panels. Industry insights reveal that the U.S. government invested over USD 2 billion in genomic initiatives between 2020–2024, fueling advancements in personalized medicine and population genomics. Market opportunities are particularly strong in oncology, where 44% of oncologists rely on NGS to guide treatment selection. Additionally, 38% of biopharmaceutical companies in the U.S. use NGS data in drug development pipelines.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 68% adoption of NGS in oncology diagnostics and 54% utilization in rare disease testing drive global demand.
• Major Market Restraint: 39% of labs report high sequencing costs as a barrier, while 33% face limited bioinformatics infrastructure.
• Emerging Trends: 42% adoption of liquid biopsy NGS and 36% implementation of single-cell sequencing highlight innovation trends.
• Regional Leadership: North America holds 44% of the global NGS market, followed by Europe at 28% and Asia-Pacific at 23%.
• Competitive Landscape: 46% of the market share is dominated by Illumina, Thermo Fisher, and Roche, with 32% shared by emerging firms.
• Market Segmentation: 58% usage in oncology, 26% in rare disease diagnostics, and 16% in reproductive health drive applications.
• Recent Development: 41% of companies launched new sequencing platforms in 2024, and 38% integrated AI into NGS data analysis.

NGS Market Latest Trends

The NGS market is experiencing strong adoption across oncology, reproductive health, infectious disease diagnostics, and personalized medicine. More than 1.2 million whole-genome sequences were generated in 2024, compared with approximately 500,000 in 2020, while 72% of cancer centers globally use NGS-based panels to identify actionable mutations. In infectious disease diagnostics, 39% of laboratories utilize NGS for pathogen surveillance, strengthening genomic monitoring and outbreak detection.

NGS adoption is also expanding into advanced research applications. Single-cell sequencing adoption increased by 34% between 2022 and 2024, supporting drug discovery, immunotherapy research, and cellular-level disease analysis. The technology is increasingly becoming a core component of precision medicine as healthcare providers and research institutions seek faster, more comprehensive genomic insights.

How is Technological Advancement Driving the NGS Market?

Technological advancement is significantly driving the NGS market by improving sequencing speed, accuracy, scalability, and data analysis capabilities. Sequencing throughput has increased substantially over the last decade, while sequencing costs have declined, enabling broader adoption across oncology, rare disease diagnostics, reproductive health, and research. The growing use of AI-powered bioinformatics is also accelerating genomic data interpretation, with 38% of companies integrating AI into NGS data analysis.

NGS Market Dynamics

DRIVER

"Rising clinical adoption is a key driver of NGS market growth."

Clinical adoption of NGS is expanding rapidly as healthcare providers increasingly use genomic information to support precision medicine. Around 72% of cancer centers worldwide have incorporated NGS into their precision oncology programs, while 35% of cancer patients underwent NGS-based therapy selection in 2024. Rare disease testing has also expanded, with adoption reaching 54%, enabling clinicians to identify genetic conditions more efficiently.

Population genomics is further strengthening demand, with programs across more than 110 countries collectively sequencing over 20 million genomes. Pharmaceutical companies are also increasing their reliance on sequencing data, with 44% using NGS information for biomarker discovery and drug development, making the technology increasingly important across clinical and biopharmaceutical workflows.

RESTRAINT

"High sequencing costs and bioinformatics challenges restrain NGS adoption."

High sequencing expenses remain a significant barrier, particularly for laboratories operating with limited healthcare and research budgets. Approximately 39% of laboratories identify sequencing costs as a major challenge, while expensive equipment, sample preparation, data processing, and storage requirements can increase the overall cost of NGS implementation.

Limited bioinformatics infrastructure further restricts adoption, with 33% of laboratories reporting insufficient capabilities for analyzing and managing genomic datasets. Around 28% of healthcare providers also experience difficulties integrating sequencing results into electronic health records, while regulatory compliance requirements can create additional delays in clinical implementation.

OPPORTUNITY

"Liquid biopsy and single-cell sequencing present strong market opportunities."

Liquid biopsy is emerging as an important opportunity for NGS because it enables genomic analysis from minimally invasive samples and supports cancer detection, treatment monitoring, and biomarker identification. Around 42% of clinical research trials adopted liquid biopsy technologies in 2024, while 38% of pharmaceutical companies incorporated liquid-biopsy-derived NGS data into oncology development pipelines.

Single-cell sequencing is another rapidly expanding application, with adoption increasing by 34% between 2022 and 2024. The technology enables researchers to examine individual cellular populations, supporting drug discovery, immunotherapy development, tumor profiling, and disease research while expanding the role of NGS beyond conventional bulk sequencing.

CHALLENGE

"Data interpretation and regulatory complexity remain key challenges."

The increasing volume and complexity of sequencing data create significant analytical challenges for NGS users. Around 31% of institutions cite limited bioinformatics expertise as a barrier to large-scale implementation, while 28% of laboratories experience data-storage difficulties as sequencing throughput continues to increase. A single human genome can generate up to 200 GB of raw data, creating substantial requirements for computational infrastructure.

Regulatory and clinical workflow integration also remain challenging. Approximately 25% of regulatory agencies impose strict requirements for clinical sequencing, which can lengthen approval processes, while 27% of healthcare providers report difficulties incorporating genomic results into routine clinical workflows. Cybersecurity is another concern, particularly for organizations managing large volumes of sensitive genomic information.

Why is Demand Increasing for the NGS Industry?

Demand for the NGS industry is increasing primarily because of the growing need for precision medicine, cancer diagnostics, rare disease identification, and personalized treatment planning. Approximately 72% of cancer centers globally use NGS-based panels, while 35% of cancer patients underwent NGS-guided therapy selection in 2024. NGS enables healthcare providers to identify genetic mutations and biomarkers more efficiently, supporting targeted treatment decisions and improving diagnostic capabilities. Rare disease testing is another important demand driver, with 54% adoption reported in this application.

NGS Market Segmentation

The NGS market segmentation is defined by type, application, and end-user adoption across research and clinical domains. Market research highlights that 58% of applications are in oncology, 26% in rare disease diagnostics, and 16% in reproductive health. Industry analysis shows that by type, NovaSeq and NextSeq platforms dominate global sequencing output, accounting for more than 70% of installed systems in 2024. Market insights reveal that academic institutions and hospitals remain the largest end-users, with 64% of all NGS usage attributed to these organizations. Market opportunities exist in expanding applications such as infectious disease surveillance, with 39% of labs globally using NGS for viral and bacterial sequencing.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

NovaSeq: NovaSeq platforms represent the leading high-throughput sequencing category, with more than 8,000 systems installed worldwide by 2024. The platform accounts for 44% of global sequencing throughput and supports large-scale applications such as population genomics, oncology, rare disease research, and pharmaceutical studies.

The platform's scalability and high processing capacity have strengthened its adoption among academic institutions, sequencing centers, pharmaceutical companies, and clinical research organizations. Its ability to process large numbers of samples efficiently also supports declining per-sample costs and the expansion of large-scale genomic studies.

NextSeq: NextSeq systems are widely used for mid-throughput sequencing applications and had more than 12,000 systems installed globally in 2024. The platform contributes 26% of sequencing output and is particularly important for academic institutions, research centers, and hospitals requiring flexible sequencing capacity.

NextSeq adoption is expanding across oncology, transcriptomics, epigenetics, and targeted sequencing. Around 54% of research centers in Europe rely on NextSeq systems for various genomic studies, while hospitals are increasingly applying the platform to targeted cancer and rare disease testing.

BY APPLICATION

Academic Institutes & Research Centers: Academic institutions and research centers account for 49% of global NGS usage. Universities and research organizations have sequenced more than 600,000 human genomes through research and population genomics programs, supporting advances in cancer research, genetic disease analysis, and precision medicine.

Approximately 58% of academic NGS research focuses on cancer and genetic diseases, while agricultural and microbial genomics represent another major area of application. Collaboration with pharmaceutical companies is also increasing, with 41% of drug discovery programs utilizing NGS data generated through academic research.

Hospitals & Clinics: Hospitals and clinics represent 38% of global NGS usage, with clinical applications expanding particularly in oncology and rare disease diagnosis. Around 72% of cancer hospitals have incorporated NGS-based testing into precision oncology programs, while 44% of rare disease diagnostics in hospitals now utilize NGS panels.

NGS adoption is also expanding into reproductive health and infectious disease management. Approximately 26% of fertility clinics use NGS for preimplantation genetic screening, while 39% of hospitals employ sequencing to identify viral and bacterial pathogens, strengthening the role of genomic diagnostics in routine healthcare.

Which Segment is Growing Faster in the NGS Market?

The NextSeq segment is positioned for faster expansion within the NGS market based on its broad adoption across academic institutions, hospitals, and mid-throughput clinical applications. NextSeq systems are increasingly used for oncology, transcriptomics, epigenetics, targeted sequencing, and rare disease testing because they provide a balance between sequencing capacity and operational cost. Its adoption is supported by growing demand for decentralized diagnostics and mid-sized sequencing workflows, particularly among hospitals and research centers.

Regional Outlook of the NGS Market

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America remains the leading region in the NGS market, supported by advanced genomic research infrastructure, widespread clinical sequencing, and strong biotechnology investment. The region accounts for 44% of global market share, with the United States representing the primary source of demand through extensive oncology testing, precision medicine programs, population genomics, and pharmaceutical research. More than 520,000 genomes were sequenced in the U.S. within one year, while over 200 genomic centers support research and clinical applications.

NGS adoption is also expanding across Canadian healthcare institutions, particularly in oncology and rare disease diagnostics. Approximately 72% of U.S. cancer hospitals use NGS-based diagnostics, while 38% of Canadian hospitals employ sequencing for oncology and rare disease applications. Strong government research funding, biotechnology partnerships, advanced bioinformatics infrastructure, and increasing integration of genomic data into clinical workflows continue to support market expansion.

EUROPE

Europe represents a major NGS market supported by government-backed genomics programs, clinical diagnostics, pharmaceutical research, and precision medicine initiatives. The region accounts for 28% of global market share, with more than 84 million patients benefiting from NGS-based testing in 2024. Approximately 47% of European hospitals have integrated NGS into clinical diagnostics, while large-scale national genomics programs continue to expand sequencing capacity and clinical applications.

The United Kingdom, Germany, France, Italy, and Spain are strengthening adoption through investments in genomic medicine, cancer research, bioinformatics, and translational healthcare. The UK's Genomics England program has sequenced more than 200,000 genomes, while France's national genomics initiatives are expanding high-throughput sequencing capabilities. Increasing collaboration between hospitals, universities, biotechnology companies, and pharmaceutical organizations is further supporting NGS adoption across clinical and research applications.

ASIA-PACIFIC

Asia-Pacific is experiencing rapid NGS adoption, driven by healthcare modernization, large-scale genomic programs, biotechnology development, and increasing clinical use of sequencing. The region accounts for 23% of the global NGS market, with China, Japan, and India serving as major contributors. China has demonstrated large-scale sequencing capabilities through infectious disease surveillance, while Japan continues to invest heavily in genomic medicine and precision healthcare. India is also expanding NGS adoption across oncology, genetic disease diagnostics, and research institutions.

The region's growth is further supported by government-funded genomics programs, expanding sequencing centers, and improving bioinformatics infrastructure. Approximately 64% of sequencing activity in Asia-Pacific is associated with infectious disease surveillance and oncology, while hospitals and research organizations increasingly use NGS for personalized medicine, population genomics, and translational research. Growing collaboration between biotechnology companies, pharmaceutical firms, universities, and healthcare providers is expected to strengthen adoption.

MIDDLE EAST & AFRICA

The Middle East & Africa NGS market is expanding as governments, hospitals, research institutions, and biotechnology companies increase investments in genomic medicine and advanced diagnostics. The region accounts for 5% of the global NGS market, with Saudi Arabia, the UAE, and South Africa leading adoption. Genomic sequencing is gaining importance in oncology, rare disease diagnosis, infectious disease surveillance, and personalized healthcare.

Government-backed healthcare transformation programs are supporting the development of genomic research centers and clinical sequencing infrastructure. Around 39% of hospitals in the UAE have integrated NGS into oncology diagnostics, while South African research centers increasingly use sequencing for infectious disease surveillance. Investments in mobile sequencing, bioinformatics, biotechnology hubs, and precision medicine are also helping extend NGS capabilities to broader patient populations.

Which Region Dominates the NGS Industry?

North America dominates the NGS industry, accounting for approximately 44% of the global market. The region benefits from advanced healthcare infrastructure, extensive genomic research programs, strong biotechnology capabilities, and high clinical adoption. In the United States, more than 520,000 genome sequences were completed in 2024, while 72% of cancer centers utilize NGS-based diagnostics. Government-backed genomic research, pharmaceutical investment, and growing adoption of precision medicine further reinforce North America's leadership.

List of Top NGS Companies

• Becton, Dickinson and Company
• Hoffmann-La Roche AG
• 10x Genomics
• PerkinElmer, Inc.
• Roche
• Qiagen N.V.
• Agilent Technologies, Inc.
• Genewiz
• Beckman Coulter (A Subsidiary of Danaher)
• Eurofins Scientific
• Thermo Fisher Scientific Inc.
• Macrogen, Inc.
• Oxford Nanopore Technologies, Ltd.
• BGI
• Illumina, Inc.
• Pacific Biosciences of California, Inc.

Top Two Companies With Heighest Market Share

• Illumina, Inc.: Illumina remains the global leader in NGS, with over 80% of global sequencing data generated using its platforms by 2024. 
• Thermo Fisher Scientific Inc.: Thermo Fisher dominates in NGS reagents, consumables, and platforms, accounting for 32% of sequencing-related sales in 2024.

Investment Analysis and Opportunities

The NGS market presents strong investment opportunities across clinical diagnostics, research, and pharmaceutical applications. Market research shows that more than 42% of new investments in 2024 targeted sequencing-based oncology diagnostics. Industry reports reveal that 38% of venture capital funding in genomics was allocated to NGS companies, with over 120 startups emerging globally. Market analysis highlights liquid biopsy as a high-growth opportunity, adopted in 42% of oncology trials. Single-cell sequencing is also expanding, with 34% growth in adoption between 2022–2024.

New Product Development

New product development in the NGS market is driven by innovation in sequencing technology, reagents, and software. Market research shows that 41% of companies launched new sequencing platforms in 2024. Industry insights reveal that 35% of these products included AI-driven bioinformatics tools for faster analysis. Liquid biopsy NGS kits, launched by 22% of major players, represent a growing segment in oncology diagnostics. Market analysis indicates that 29% of new systems introduced between 2022–2024 focused on single-cell sequencing, supporting immunotherapy and drug discovery.

Five Recent Developments

• January 2026 – Illumina expands genomic sequencing collaborations for precision oncology research Illumina expanded collaborations focused on genomic sequencing for precision oncology, supporting large-scale genome analysis and enabling researchers to identify clinically relevant genetic variations for cancer research and targeted treatment development.
• February 2026 – Thermo Fisher Scientific advances liquid biopsy NGS solutions for oncology testing Thermo Fisher Scientific expanded its liquid biopsy next-generation sequencing solutions, supporting minimally invasive cancer testing and enabling laboratories to analyze circulating tumor DNA for biomarker identification.
• April 2026 – BGI expands genomic sequencing capabilities for infectious disease surveillance BGI advanced large-scale genomic sequencing capabilities for infectious disease surveillance, supporting rapid pathogen identification, genomic monitoring, and research into emerging infectious disease variants.
• May 2026 – Oxford Nanopore Technologies advances portable sequencing for field diagnostics Oxford Nanopore Technologies expanded portable sequencing solutions with improved throughput and real-time analysis capabilities, supporting rapid genomic testing in decentralized laboratories and field-based diagnostic environments.
• July 2026 – 10x Genomics expands single-cell sequencing solutions for biomedical research  10x Genomics expanded its single-cell sequencing technologies, enabling researchers to analyze cellular characteristics and molecular interactions at greater resolution across genomics, immunology, oncology, and biomedical research applications.

Report Coverage of NGS Market

The NGS market report covers detailed analysis of market size, share, industry growth, and competitive landscape across key regions and applications. Market research highlights that over 1.2 million genomes were sequenced globally in 2024, with oncology contributing 58% of applications. Industry insights show that academic institutes accounted for 49% of sequencing activity, while hospitals contributed 38%. Between 2024 and 2027, over 15 million new genomes are expected to be sequenced under global population genomics programs. By 2030, more than 25 million liquid biopsy tests will use NGS platforms.

NGS Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 9358.42 Million in 2026
Market Size Value By	USD 28068.3 Million by 2035
Growth Rate	CAGR of 12.98% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : NovaSeq NextSeq Sequel Nanopore By Application : Academic Institutes & Research Centers Hospitals & Clinics Pharmaceutical & Biotechnology Companies Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample